Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions

被引：198

作者：

Hato, Tai ^{[1
]}

Goyal, Lipika ^{[2
]}

Greten, Tim F. ^{[3
]}

Duda, Dan G. ^{[1
]}

Zhu, Andrew X. ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA

[3] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA

来源：

HEPATOLOGY | 2014年 / 60卷 / 05期

基金：

美国国家卫生研究院;

关键词：

REGULATORY T-CELLS; PERCUTANEOUS ETHANOL INJECTION; SUPPRESSOR-CELLS; POSTOPERATIVE RECURRENCE; CTLA-4; BLOCKADE; LIVER; RESPONSES; PD-1; MOLECULES; HEPATITIS;

D O I：

10.1002/hep.27246

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

引用

页码：1776 / 1782

页数：7

共 50 条

[31] Immune Checkpoint Inhibitors and Glioblastoma:A Review on Current State and Future Directions [J].

Ser, Merve Hazal ;

Webb, Mason J. ;

Sener, Ugur ;

Campian, Jian L. .

JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2024, 7 (02) :97-110

[32] Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma [J].

Cui, Tian-ming ;

Liu, Yao ;

Wang, Jia-bei ;

Liu, Lian-xin .

ONCOTARGETS AND THERAPY, 2020, 13 :11725-11740

[33] Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? [J].

Carloni, Riccardo ;

Rizzo, Alessandro ;

Ricci, Angela Dalia ;

Frega, Giorgio ;

Di Federico, Alessandro ;

Palloni, Andrea ;

Di Marco, Mariacristina ;

Gadaleta-Caldarola, Gennaro ;

Brandi, Giovanni .

FUTURE ONCOLOGY, 2022, 18 (08) :1023-1034

[34] Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions [J].

Riccardo Inchingolo ;

Alessandro Posa ;

Martin Mariappan ;

Stavros Spiliopoulos .

World Journal of Gastroenterology, 2019, 25 (32) :4614-4628

[35] Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions [J].

Inchingolo, Riccardo ;

Posa, Alessandro ;

Mariappan, Martin ;

Spiliopoulos, Stavros .

WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (32) :4614-4628

[36] Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma [J].

Tykodi, Scott S. .

IMMUNOTHERAPY, 2013, 5 (06) :607-619

[37] Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions [J].

Zibelman, Matthew ;

Ghatalia, Pooja ;

Geynisman, Daniel M. ;

Plimack, Elizabeth R. .

IMMUNOTHERAPY, 2016, 8 (07) :785-798

[38] Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? [J].

Reparaz, David ;

Aparicio, Belen ;

Llopiz, Diana ;

Hervas-Stubbs, Sandra ;

Sarobe, Pablo .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (04)

[39] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance [J].

Pelizzaro, Filippo ;

Farinati, Fabio ;

Trevisani, Franco .

BIOMEDICINES, 2023, 11 (04)

[40] Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases [J].

Cai, Xin ;

Zhan, Huajie ;

Ye, Yuguang ;

Yang, Jinjin ;

Zhang, Minghui ;

Li, Jing ;

Zhuang, Yuan .

FRONTIERS IN GENETICS, 2021, 12

← 1 2 3 4 5 →